Nanoparticles and clinically applicable cell tracking

Bernsen, Monique R.; Guenoun, Jamal; Tiel, Sandra T. van; Krestin, Gabriël P.

doi:10.1259/bjr.20150375

Cited by 28 publications

(27 citation statements)

References 143 publications

(188 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To render cells detectable, a contrast agent is incorporated into cells prior to transplantation. Superparamagnetic particles of iron oxide (SPIO) and gold nanoparticles (AuNPs) are examples of widely studied contrast agents for MRI and CT, respectively (11,12). One limitation of both these approaches is the lack of specificity of the signal produced by the labeled cells, which makes it difficult to non-equivocally distinguish the signal of labeled cells from other sources of hyperdensities (microhemorrhages or calcifications for instance).…”

Section: Ivyspring International Publishermentioning

confidence: 99%

Multicolor spectral photon counting CT monitors and quantifies therapeutic cells and their encapsulating scaffold in a model of brain damage

Cuccione¹,

Chhour²,

Dumot³

et al. 2020

Nanotheranostics

View full text Add to dashboard Cite

Rationale & aim: Various types of cell therapies are currently under investigation for the treatment of ischemic stroke patients. To bridge the gap between cell administration and therapeutic outcome, there is a need for non-invasive monitoring of these innovative therapeutic approaches. Spectral photon counting computed tomography (SPCCT) is a new imaging modality that may be suitable for cell tracking. SPCCT is the next generation of clinical CT that allows the selective visualization and quantification of multiple contrast agents. The aims of this study are: (i) to demonstrate the feasibility of using SPCCT to longitudinally monitor and quantify therapeutic cells, i.e. bone marrow-derived M2-polarized macrophages transplanted in rats with brain damage; and (ii) to evaluate the potential of this approach to discriminate M2-polarized macrophages from their encapsulating scaffold. Methods: Twenty one rats received an intralesional transplantation of bone marrow-derived M2-polarized macrophages. In the first set of experiments, cells were labeled with gold nanoparticles and tracked for up to two weeks post-injection in a monocolor study via gold K-edge imaging. In the second set of experiments, the same protocol was repeated for a bicolor study, in which the labeled cells are embedded in iodine nanoparticle-labeled scaffold. The amount of gold in the brain was longitudinally quantified using gold K-edge images reconstructed from SPCCT acquisition. Animals were sacrificed at different time points post-injection, and ICP-OES was used to validate the accuracy of gold quantification from SPCCT imaging. Results: The feasibility of therapeutic cell tracking was successfully demonstrated in brain-damaged rats with SPCCT imaging. The imaging modality enabled cell monitoring for up to 2 weeks post-injection, in a specific and quantitative manner. Differentiation of labeled cells and their embedding scaffold was also feasible with SPCCT imaging, with a detection limit as low as 5,000 cells in a voxel of 250 × 250 × 250 µm in dimension in vivo. Conclusion: Multicolor SPCCT is an innovative translational imaging tool that allows monitoring and quantification of therapeutic cells and their encapsulating scaffold transplanted in the damaged rat brain.

show abstract

Section: Ivyspring International Publishermentioning

confidence: 99%

Multicolor spectral photon counting CT monitors and quantifies therapeutic cells and their encapsulating scaffold in a model of brain damage

Cuccione¹,

Chhour²,

Dumot³

et al. 2020

Nanotheranostics

View full text Add to dashboard Cite

show abstract

“…This study aims to establish and characterize optimized protocols to monitor MSCs using a genetically engineered MSCs model labeled with iron oxide nanoparticles and visualized using MRI. To the best of our knowledge, there is no clinically approved iron oxide nanoparticle formulation to label MSCs (most clinically approved iron oxide nanoparticles were discontinued from the market due to safety or other reasons, 31 and the usage of the FDA-approved Ferumoxytol iron oxide nanoparticles to label the cells for MRI applications is considered as an "off label" use because it is only approved clinically to treat anemia patients with kidney diseases 32,33 ), and hence it is vital to fill this missing gap and present potential labeling formulations to the research community for further investigations.…”

Section: Discussionmentioning

confidence: 99%

<p>Efficient Labeling Of Mesenchymal Stem Cells For High Sensitivity Long-Term MRI Monitoring In Live Mice Brains</p>

Ali¹,

Shahror²,

Chen³

2020

IJN

View full text Add to dashboard Cite

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/R_ECxLGJvxw Background: Regenerative medicine field is still lagging due to the lack of adequate knowledge regarding the homing of therapeutic cells towards disease sites, tracking of cells during treatment, and monitoring the biodistribution and fate of cells. Such necessities require labeling of cells with imaging agents that do not alter their biological characteristics, and development of suitable non-invasive imaging modalities. Purpose: We aimed to develop, characterize, and standardize a facile labeling strategy for engineered mesenchymal stem cells without altering their viability, secretion of FGF21 protein (neuroprotective), and differentiation capabilities for non-invasive longitudinal MRI monitoring in live mice brains with high sensitivity. Methods: We compared the labeling efficiency of different commercial iron oxide nanoparticles towards our stem cells and determined the optimum labeling conditions using prussian blue staining, confocal microscopy, transmission electron microscopy, and flow cytometry. To investigate any change in biological characteristics of labeled cells, we tested their viability by WST-1 assay, expression of FGF21 by Western blot, and adipogenic and osteogenic differentiation capabilities. MRI contrast-enhancing properties of labeled cells were investigated in vitro using cell-agarose phantoms and in mice brains transplanted with the therapeutic stem cells. Results: We determined the nanoparticles that showed best labeling efficiency and least extracellular aggregation. We further optimized their labeling conditions (nanoparticles concentration and media supplementation) to achieve high cellular uptake and minimal extracellular aggregation of nanoparticles. Cell viability, expression of FGF21 protein, and differentiation capabilities were not impeded by nanoparticles labeling. Low number of labeled cells produced strong MRI signal decay in phantoms and in live mice brains which were visible for 4 weeks post transplantation. Conclusion: We established a standardized magnetic nanoparticle labeling platform for stem cells that were monitored longitudinally with high sensitivity in mice brains using MRI for regenerative medicine applications.

show abstract

“…Organ failure is a catastrophic phenomenon of many human chronic debilitating diseases. Plasticity and migration capacity of stem cells has opened up new prospects towards treating a wide range of human diseases in recent years and sheds light on expanding fields of regenerative medicine . Cell‐based therapy is an interdisciplinary field in regenerative medicine, which can treat such disorders by application of therapeutic cells instead of organ transplantation .…”

Section: Introductionmentioning

confidence: 99%

Optical fluorescence imaging with shortwave infrared light emitter nanomaterials for in vivo cell tracking in regenerative medicine

Fath‐Bayati

Vasei

Sharif‐Paghaleh

2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

In vivo tracking and monitoring of adoptive cell transfer has a distinct importance in cell‐based therapy. There are many imaging modalities for in vivo monitoring of biodistribution, viability and effectiveness of transferred cells. Some of these procedures are not applicable in the human body because of low sensitivity and high possibility of tissue damages. Shortwave infrared region (SWIR) imaging is a relatively new technique by which deep biological tissues can be potentially visualized with high resolution at cellular level. Indeed, scanning of the electromagnetic spectrum (beyond 1000 nm) of SWIR has a great potential to increase sensitivity and resolution of in vivo imaging for various human tissues. In this review, molecular imaging modalities used for monitoring of biodistribution and fate of administered cells with focusing on the application of non‐invasive optical imaging at shortwave infrared region are discussed in detail.

show abstract

Nanoparticles and clinically applicable cell tracking

Cited by 28 publications

References 143 publications

Multicolor spectral photon counting CT monitors and quantifies therapeutic cells and their encapsulating scaffold in a model of brain damage

Multicolor spectral photon counting CT monitors and quantifies therapeutic cells and their encapsulating scaffold in a model of brain damage

<p>Efficient Labeling Of Mesenchymal Stem Cells For High Sensitivity Long-Term MRI Monitoring In Live Mice Brains</p>

Optical fluorescence imaging with shortwave infrared light emitter nanomaterials for in vivo cell tracking in regenerative medicine

Contact Info

Product

Resources

About